Jazz Pharmaceuticals (NASDAQ:JAZZ) Receives “Overweight” Rating from Piper Sandler

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “overweight” rating reiterated by research analysts at Piper Sandler in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $176.00 price objective on the specialty pharmaceutical company’s stock, up from their previous price objective of $163.00. Piper Sandler’s target price suggests a potential upside of 19.90% from the stock’s previous close.

JAZZ has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Royal Bank of Canada reduced their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday. Needham & Company LLC raised their target price on shares of Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, TD Cowen lowered their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $181.80.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded up $7.13 during trading hours on Wednesday, hitting $146.80. The stock had a trading volume of 1,330,831 shares, compared to its average volume of 658,309. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $148.06. The stock’s 50 day moving average is $125.42 and its 200 day moving average is $118.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market capitalization of $8.87 billion, a PE ratio of 20.68, a PEG ratio of 1.04 and a beta of 0.56.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 5,053 shares of company stock valued at $617,442 over the last quarter. 4.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in JAZZ. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth about $25,000. Quadrant Capital Group LLC increased its stake in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Elequin Capital LP lifted its stake in Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 183 shares in the last quarter. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $28,000. Finally, Allianz SE acquired a new stake in Jazz Pharmaceuticals during the fourth quarter worth $29,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.